IBD Clinical

Here, we aim to document delivery of the following objectives using CCCare: describe the unmet need for more effectively delivered IBD therapy, as defined by the current proportion of patients with active disease;and provide an accurate picture of IBD severity, therapy, and complications in a real-world cohort of patients with IBD under usual care at two large IBD services. B 1 b B Ustekinumab treatment persistence in Crohn's disease: An Australian real-world study b TH Chien SP 1 sp , TH-W Huang SP 1 sp , A Puig SP 1 sp , B T Khuong b SP 2 sp , MH Kouhkamari SP 2 sp and S Che SP 2 sp SP 1 sp I Janssen-Cilag Pty Ltd, Sydney, New South Wales, Australia;i SP 2 sp I Prospection Pty Ltd, Sydney, New South Wales, Australia i B I Background and Aim: i b Real-world studies in patients with Crohn's disease (CD) have shown that persistence with therapy is a strong predictor for major and sustained favorable outcomes. B 268 b B Challenges of dysplasia screening in patients with inflammatory bowel disease: A retrospective review of screening at a single tertiary health care network b B A Elford b , S Bell, G Moore and M Swan I Monash Health, Melbourne, Victoria, Australia i B I Background and Aim: i b The Australian guidelines for colonoscopic surveillance and management of dysplasia in patients with inflammatory bowel disease (IBD) were updated in 2019. Dose escalation failed in 23 patients, with seven (30.4%) requiring further dose escalation, one patient (4.3%%) switching to a drug within the same class, and seven patients (30.4%) switching to a drug in a different class. B I Conclusion: i b Secondary LOR to treatment affects a significant number of patients with IBD. [Extracted from the article] Copyright of Journal of Gastroenterology & Hepatology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)